Letolizumab

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameLetolizumab
Drug Alias NameBMS-986004BMS2h-572-633-CT-L2
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD40 ligand inhibitors
TargetsCD40 ligand
Therapy Area/IndicationsGraft vs Host DiseasePurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyH Lee Moffitt Cancer Center & Research Institute
Inactive CompaniesN/A
Active IndicationsGraft vs Host Disease
Inactive IndicationsPurpura, Thrombocytopenic, Idiopathic

Other Information

ATC CodeN/A
Related LinksN/A